Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG
<b>Background</b>: The investigation of the antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay with four widely-used commercial serological assays for the det...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/9/4/733 |
| _version_ | 1797539333588123648 |
|---|---|
| author | Kirsten Alexandra Eberhardt Felix Dewald Eva Heger Lutz Gieselmann Kanika Vanshylla Maike Wirtz Franziska Kleipass Wibke Johannis Philipp Schommers Henning Gruell Karl August Brensing Roman-Ulrich Müller Max Augustin Clara Lehmann Manuel Koch Florian Klein Veronica Di Cristanziano |
| author_facet | Kirsten Alexandra Eberhardt Felix Dewald Eva Heger Lutz Gieselmann Kanika Vanshylla Maike Wirtz Franziska Kleipass Wibke Johannis Philipp Schommers Henning Gruell Karl August Brensing Roman-Ulrich Müller Max Augustin Clara Lehmann Manuel Koch Florian Klein Veronica Di Cristanziano |
| author_sort | Kirsten Alexandra Eberhardt |
| collection | DOAJ |
| description | <b>Background</b>: The investigation of the antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay with four widely-used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) proteins. <b>Methods:</b> Serum samples were taken from an unbiased group of convalescent patients and from a negative control group. Sample were simultaneously analyzed by the new Immundiagnostik IDK<sup>®</sup> anti-SARS-CoV-2 S1 IgG assay, by the DiaSorin LIAISON<sup>®</sup> SARS-CoV-2 S1/S2 IgG assay, and by the Euroimmun anti-SARS-CoV-2 S1 IgG ELISA. Antibodies binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the pan-immunoglobulin immunoassay Roche Elecsys<sup>®</sup> anti-SARS-CoV-2. Moreover, we investigated samples of a group of COVID-19 convalescent subjects that were primarily tested S1 IgG non-reactive. Samples were also tested by live virus and pseudovirus neutralization tests. <b>Results:</b> Overall, the IDK® anti-SARS-CoV-2 S1 IgG assay showed the highest sensitivity among the evaluated spike (S) protein-based assays. Additionally, the Immundiagnostik assay correlated well with serum-neutralizing activity. <b>Conclusions:</b> The novel IDK<sup>®</sup> anti-SARS-CoV-2 S1 IgG assay showed high sensitivity and specificity, representing a valid option for use in the routine diagnostic. |
| first_indexed | 2024-03-10T12:43:33Z |
| format | Article |
| id | doaj.art-6c630c7a08bd4ce88b38dcb9bbf93f92 |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-10T12:43:33Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-6c630c7a08bd4ce88b38dcb9bbf93f922023-11-21T13:40:11ZengMDPI AGMicroorganisms2076-26072021-03-019473310.3390/microorganisms9040733Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgGKirsten Alexandra Eberhardt0Felix Dewald1Eva Heger2Lutz Gieselmann3Kanika Vanshylla4Maike Wirtz5Franziska Kleipass6Wibke Johannis7Philipp Schommers8Henning Gruell9Karl August Brensing10Roman-Ulrich Müller11Max Augustin12Clara Lehmann13Manuel Koch14Florian Klein15Veronica Di Cristanziano16Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute for Clinical Chemistry, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyNierenzentrum Bonn, Godesberger Allee 26, 53175 Bonn, GermanyCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, GermanyDepartment I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, GermanyCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, GermanyCenter for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, GermanyInstitute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany<b>Background</b>: The investigation of the antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared the new Immundiagnostik IDK® anti-SARS-CoV-2 S1 IgG assay with four widely-used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) proteins. <b>Methods:</b> Serum samples were taken from an unbiased group of convalescent patients and from a negative control group. Sample were simultaneously analyzed by the new Immundiagnostik IDK<sup>®</sup> anti-SARS-CoV-2 S1 IgG assay, by the DiaSorin LIAISON<sup>®</sup> SARS-CoV-2 S1/S2 IgG assay, and by the Euroimmun anti-SARS-CoV-2 S1 IgG ELISA. Antibodies binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the pan-immunoglobulin immunoassay Roche Elecsys<sup>®</sup> anti-SARS-CoV-2. Moreover, we investigated samples of a group of COVID-19 convalescent subjects that were primarily tested S1 IgG non-reactive. Samples were also tested by live virus and pseudovirus neutralization tests. <b>Results:</b> Overall, the IDK® anti-SARS-CoV-2 S1 IgG assay showed the highest sensitivity among the evaluated spike (S) protein-based assays. Additionally, the Immundiagnostik assay correlated well with serum-neutralizing activity. <b>Conclusions:</b> The novel IDK<sup>®</sup> anti-SARS-CoV-2 S1 IgG assay showed high sensitivity and specificity, representing a valid option for use in the routine diagnostic.https://www.mdpi.com/2076-2607/9/4/733pandemichumoral responseneutralizationtiterprotectionnon-responder |
| spellingShingle | Kirsten Alexandra Eberhardt Felix Dewald Eva Heger Lutz Gieselmann Kanika Vanshylla Maike Wirtz Franziska Kleipass Wibke Johannis Philipp Schommers Henning Gruell Karl August Brensing Roman-Ulrich Müller Max Augustin Clara Lehmann Manuel Koch Florian Klein Veronica Di Cristanziano Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG Microorganisms pandemic humoral response neutralization titer protection non-responder |
| title | Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG |
| title_full | Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG |
| title_fullStr | Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG |
| title_full_unstemmed | Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG |
| title_short | Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG |
| title_sort | evaluation of a new spike s protein based commercial immunoassay for the detection of anti sars cov 2 igg |
| topic | pandemic humoral response neutralization titer protection non-responder |
| url | https://www.mdpi.com/2076-2607/9/4/733 |
| work_keys_str_mv | AT kirstenalexandraeberhardt evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT felixdewald evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT evaheger evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT lutzgieselmann evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT kanikavanshylla evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT maikewirtz evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT franziskakleipass evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT wibkejohannis evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT philippschommers evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT henninggruell evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT karlaugustbrensing evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT romanulrichmuller evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT maxaugustin evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT claralehmann evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT manuelkoch evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT florianklein evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg AT veronicadicristanziano evaluationofanewspikesproteinbasedcommercialimmunoassayforthedetectionofantisarscov2igg |